

**DECLARATION FORM ON NOTHING TO DECLARE OR NOTHING NEW TO
DECLARE FOR USE IN THE INFORMATION EXCHANGE**

Measure	Nothing to declare	Nothing new to declare
A, part I	<input type="checkbox"/>	<input type="checkbox"/>
A, part 2 (i)	<input type="checkbox"/>	<input type="checkbox"/>
A, part 2 (ii)	<input type="checkbox"/>	<input type="checkbox"/>
A, part 2 (iii)	<input type="checkbox"/>	<input type="checkbox"/>
B (i)	<input type="checkbox"/>	<input type="checkbox"/>
B (ii)	<input checked="" type="checkbox"/>	<input type="checkbox"/>
C	<input type="checkbox"/>	<input type="checkbox"/>
D	<input type="checkbox"/>	<input type="checkbox"/>
E	<input type="checkbox"/>	<input checked="" type="checkbox"/>
F	<input checked="" type="checkbox"/>	<input type="checkbox"/>
G	<input type="checkbox"/>	<input checked="" type="checkbox"/>

(Please mark the appropriate box(es) for each measure, with a tick.)

Date: 13 April 2007

State Party to the Convention: Finland

CONFIDENCE BUILDING MEASURE A Part 1

Exchange of Data on Research Centres and Laboratories - #1

1. Name(s) of the research centre and/or laboratory

Centre for Biothreat Preparedness

2. Responsible public or private organization or company

Centre for Military Medicine, Finnish Defence Forces under the Ministry of Defence and the National Public Health Institute under the Ministry of Social Affairs and Health.

3. Location and postal address

Tukholmankatu 8 A, FI-00290 Helsinki and Mannerheimintie 166, FIN-00300 Helsinki.

4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence

The Centre is financed jointly by the Finnish Defence Forces and the National Public Health Institute. The Scientific Advisory Board for Defence (MATINE) financed a project conducted at the Centre during the year 2006 for 37000 €

5. Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m²)

There are no BSL-4 units at the Centre.

6. If no maximum containment unit, indicate highest level of protection

BSL-3.

7. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate

The Centre for Biothreat Preparedness started its activities in May 2005. During 2006, the Centre developed rapid detection assays for selected microbial agents.

Exchange of Data on Research Centres and Laboratories -#2

- 1. Name(s) of the research centre and/or laboratory**
National Public Health Institute, Bacteriological and Virological laboratories and Biothreat unit
- 2. Responsible public or private organization or company**
National Public Health Institute under the Ministry of Social Affairs and Health
- 3. Location and postal address**
Mannerheimintie 166
FIN-00300 Helsinki
- 4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
Funding from the Ministry of Social Affairs and Health and a large variety of external research funding. Funding contribution from the Finnish Defence Forces (100.000 €).
- 5. Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m²)**
There are no BSL-4 laboratories or other units at this containment level.
- 6. If no maximum containment unit, indicate highest level of protection**
BSL-3 level laboratory.
- 7. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**
Clinical and environmental microbiological research and reference laboratory facilities in Helsinki, Turku, Kuopio and Oulu. Work mainly with ordinarily occurring endemic and epidemic bacteria and viruses with main emphases on vaccine preventable diseases, enteric pathogens, zoonoses, tuberculosis spp, enteroviruses, polioviruses, influenza, HIV, Hepatitis viruses and environmental fungi and bacteria causing human health problems. The Institute manages regional Influenza and Polio laboratory facilities. The Institute is in charge of biothreat preparedness in the public health context. National focal point for IHR starting June 2007.

Exchange of Data on Research Centres and Laboratories - #3

1. Name(s) of the research centre and/or laboratory

Yersinia Research Laboratory

2. Responsible public or private organization or company

University of Helsinki

University of Turku

3. Location and postal address

Department of Bacteriology and Immunology

Haartman Institute, University of Helsinki

Haartmaninkatu 3

P.O.Box 21

FIN-00014 University of Helsinki

Helsinki, Finland

and

Department of Medical Biochemistry

University of Turku

Kiinamylynkatu 10

FIN-20520 Turku, Finland

Yersinia-research home page: [Http://www.hi.helsinki.fi/yersinia/](http://www.hi.helsinki.fi/yersinia/)

4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence

Academy of Finland

5. Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m2)

No BSL-4 laboratories.

6. If no maximum containment unit, indicate highest level of protection

Containment level BSL-2. The studied microbes have been attenuated or are avirulent.

7. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate

The research is focused on genetics of the biosynthesis of *Yersinia pestis* lipopolysaccharide (LPS), as well as on the role of LPS in virulence. Another research topic is on *Y. pestis* specific bacteriophage receptors.

Exchange of Data on Research Centres and Laboratories - #4

- 1. Name(s) of the research centre and/or laboratory**
Department of Virology
- 2. Responsible public or private organization or company**
University of Helsinki
- 3. Location and postal address**
P.O. Box 21
Haartman Institute
00014 University of Helsinki
- 4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
Helsinki University Hospital EVO-fund, University of Helsinki, National Technology Agency of Finland, Center for Military Medicine (6 months salary in 2006), Academy of Finland, Sigrid Jusélius Foundation, European Union, University of Helsinki Funds
- 5. Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m²)**
There are no BSL-4 laboratories.
- 6. If no maximum containment unit, indicate highest level of protection**
BSL-3, 75 m² and 100 m².
- 7. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**
The Helsinki University Viral Zoonoses Group (HUVZG) conducts research on virology, cell biology, ecology and epidemiology of zoonotic viruses, especially hantaviruses and certain other rodent-borne and arboviruses occurring in Northern Europe. Our research group operates within Faculty of Medicine, Haartman Institute Department of Virology, and partially at the Division of Microbiology and Immunology at the Veterinary Faculty, has a BSL-3 facility in both faculties and is also connected to diagnostic laboratory of viral zoonoses in HUSLAB, Helsinki, and also acts as a WHO Collaborating Centre for Arbo- and Zoonotic Viruses. Principal investigators of the group are Alexander Plyusnin, Antti Vaheri and Olli Vapalahti.

Exchange of Data on Research Centres and Laboratories #5

8. Name(s) of the research centre and/or laboratory

Finnish Food Safety Authority

9. Responsible public or private organization or company

Finnish Food Safety Authority under the Ministry of Agriculture and Forestry

10. Location and postal address

Mustialankatu 3, FI-00790 Helsinki

11. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence

Financing from the Ministry of Agriculture and Forestry.

12. Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m²)

None.

13. If no maximum containment unit, indicate highest level of protection

Six containment level 3+ laboratories, total size 473,5m².

14. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate

Diagnostics of animal diseases, for example rabies, avian influenza, Newcastle disease, foot and mouth disease, classical swine fever, anthrax, tuberculosis, verotoxic E.coli.

Exchange of Data on Research Centres and Laboratories - #6

- 1. Name(s) of the research centre and/or laboratory**
Finnish Defence Forces Technical Research Centre (PVTT)
- 2. Responsible public or private organization or company**
Finnish Defence Forces Technical Research Centre (PVTT) , Finnish Defence Forces under the Ministry of Defence
- 3. Location and postal address**
P.O. Box 5
FIN-34111 Lakiala
Finland
- 4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
Finnish Defence Forces
- 5. Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m2)**
No BSL-4 laboratories.
- 6. If no maximum containment unit, indicate highest level of protection**
Bioasafety laboratory level BSL-2, 20 m3.
- 7. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**
The objective of the research work has been in the development of detection/identification methods for biowarfare microbes and toxins. The main activity in 2006 has focused on the development of a bioaerosol detection method and evaluation of commercially available detection devices and kits. A deployable NBC-laboratory for peacekeeping operations has been under development. In addition, PVTT has been involved in developing antibody based detection kits for ricin toxin. All biodefence research has been carried out with non-pathogenic strains, or otherwise harmless microbes.

Exchange of Data on Research Centres and Laboratories -#7

- 1. Name(s) of the research centre and/or laboratory**
National Public Health Institute, Department of Viral Diseases and Immunology (VIMO)
- 2. Responsible public or private organization or company**
National Public Health Institute under the Ministry of Social Affairs and Health
- 3. Location and postal address**
Mailing address: Mannerheimintie 166, FIN-00300 Helsinki, Finland
Visiting address: Hämeentie 57, FIN-00580 Helsinki, Finland
- 4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence**
Financing through the Ministry of Social Affairs and Health
- 5. Number of maximum containment units within the research centre and/or laboratory, with an indication of their respective size (m2)**
-
- 6. If no maximum containment unit, indicate highest level of protection**
BSL-3, (approximately 20 m2)
- 7. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate**
Diagnosis and research of human and avian influenza viruses of uncommon subtypes

CONFIDENCE BUILDING MEASURE A Part 2 (i, ii, iii)

National Biological Defence Research and Development Programme Declaration

Description and Facilities

The Finnish Strategy to Secure Vital Functions of Society from November 2003 (and Nov. 2006) defined vital functions of Finnish society and established targets and development policies that would guide each administrative branch of the government in dealing with its strategic tasks. The strategy called for co-operation between each government sector in combating against new threats towards society. According to the Government Report on Finnish Security and Defence Policy of 2004, terrorism and epidemics caused by infectious diseases were listed as key threats affecting national security.

Based on the above resolutions The Centre for Biothreat Preparedness started operations in Helsinki in May 2005. The Centre combines Finnish scientific and laboratory know-how on biological defence, as well as on biothreat assessment and preparedness. The Centre is actively seeking domestic and international collaboration, especially in the field of rapid detection and identification methodologies of selected biological agents. The Centre is composed of two Units; the Biological Defence Unit of the Finnish Defence Forces, and the Biological Threat Unit of the National Public Health Institute (NPHI). Scientific work is carried out in a biological safety level 3 laboratory at the NPHI facilities. Furthermore, the Centre works in close contact with the Department of Infectious Disease Epidemiology of the NPHI. In addition, the Centre has recently acquired space at a newly renovated building within the Biomedicum Helsinki Institute, where work is carried out in close contact with the BC-Defence and Environmental Health Unit of the Center for Military Medicine.

CONFIDENCE BUILDING MEASURE B

Background information on outbreaks of reportable infectious diseases

<u>Disease</u>	<u>Number of cases per year</u>							
	1999	2000	2001	2002	2003	2004	2005	2006
Tularaemia	87	926	29	106	823	151	62	475
Anthrax	0	0	0	0	0	0	0	-
Diphtheria	0	0	2	0	0	0	0	0
Febris typhoides	8	0	1	3	6	6	8	5
Febris paratyphoides	36	3	7	1	4	9	5	5
Salmonellosis alia	2801	2624	2734	2351	2170	2248	2477	2565
Ornithosis	0	0	0	0	0	0	0	-
Shigellosis	71	75	223	85	64	110	113	74
Nephropatia epidemica (Puumala virus infection)	2300	774	1057	2603	1566	1429	2402	1890

CONFIDENCE-BUILDING MEASURE C:

Encouragement of publication of results and promotion of use of knowledge

Publications:

1. Najdenski, H., E. Golkocheva, V. Kussovski, E. Ivanova, V. Manov, M. Iliev, A. Vesselinova, J. A. Bengoechea, and M. Skurnik. 2006. Experimental pig yersiniosis to assess *Yersinia enterocolitica* O:8 mutant strains. *FEMSIM* 47: 425-435.
2. Skurnik, M. and Strauch, E. 2006. Phage therapy. Facts and Fiction. *International Journal of Medical Microbiology* 296:5-14.
3. Biedzka-Sarek, M. and M. Skurnik. 2006. How to outwit the enemy: dendritic cells face *Salmonella*. *APMIS* 114: 589-600.
4. Hertwig, S., Skurnik, M., and Appel, B. 2006. Yersinia phages. In *The Bacteriophages, second edition*. Calendar, R. (ed.). Oxford University Press, pp 545-556.
5. Laakkonen J., Kallio E., Kallio-Kokko H., Vapalahti, O. Vaheri, A. and Henttonen, H. Is there an association of *Pneumocystis* infection with the presence of arena-, hanta-, and poxvirus antibodies in wild mice and shrews in Finland? *Parasitology* 132:461-466, 2006.
6. Plyusnin, A., Vaheri A., Lundkvist, Å., Klempa, B., Meisel, H., Kruger, D.H., Ulrich, R., Stanko, M. and Labuda, M. Saaremaa hantavirus should not be confused with its dangerous relative, Dobrava virus. *J. Clin. Microbiol.* 44:1608-1611, 2006.
7. Miettinen, M.H., Mäkelä, S.H., Ala-Houhala, I.O, Huhtala, H.S., Kööbi, T., Vaheri, A.I., Pasternack, A.I., Pörsti, I.H., and Mustonen, J.T., Ten-year prognosis of Puumala hantavirus-induced acute interstitial nephritis. *Kidney Int.* 69:2043-2048, 2006.
8. Kallio, E.R., Klingström, J., Gustafsson, E., Manni, T., Vaheri, A., Henttonen, H., Vapalahti, O. and Lundkvist, Å. Prolonged survival of Puumala hantavirus outside the host: evidence for indirect transmission via the environment. *J. Gen. Virol.* 87:2127-2134, 2006.
9. Alminaitte, A., Halttunen, V., Kumar, V., Vaheri, A., Holm, L. and Plyusnin, A. Oligomerization of hantavirus nucleocapsid protein: analysis of the N-terminal coiled-coil domain. *J. Virol.* 80:9073-9081, 2006.
10. Jääskeläinen, A.E., Tikkakoski, T., Uzcátegui, N.Y., Alekseev, A.N., Vaheri, A. and Vapalahti, O. Siberian subtype tick-borne encephalitis virus, Finland. *Emerg. Infect. Dis.* 12:1568-1571, 2006.
11. Laakkonen, J., Kallio-Kokko, H., Öktem, M.A., Blasdel, K., Plyusnina, A., Niemimaa, J., Plyusnin, A., Karatas, A., Vaheri, A. and Henttonen H. Serological survey for viral pathogens in Turkish rodents. *J. Wildlife Dis.* 42:672-676, 2006.
12. Kallio, E.R., Poikonen, A., Vaheri, A., Vapalahti, O., Henttonen, H., Koskela, E. and Mappes, T. Maternal antibodies postpone hantavirus infection and enhance individual breeding success. *Proc. Biol. Sci.* 273:2771-2776, 2006.

13. Kallio-Kokko, H., Laakkonen, J., Rizzoli, A., Tagliapietra, V., Cattadori, I., Perkins, S., Hudson, P.J., Cristofolini, A., Versini, W., Vapalahti, O., Vaheri, A. and Henttonen, H. Hanta- and arenavirus antibody prevalence in rodents and humans in Trentino, Northern Italy. *Epidemiol. Infect.* 134:830-836, 2006.
14. Huhtamo E, Vuorinen S, Uzcategui NY, Vapalahti O, Haapasalo H, Lumio J. Fatal dengue virus infection in a Finnish traveler. *J Clin Virol.* 2006; 37: 323--36
15. Marjelund S, Jaaskelainen A, Tikkakoski T, Tuisku S, Vapalahti O. Gadolinium enhancement of cauda equina: a new MR imaging finding in the radiculitic form of tick-borne encephalitis. *Am J Neuroradiol.* 2006;27:995-8
16. Plyusnina, A., Aberle, S., Aberle, J., and Plyusnin, A. Genetic analysis of Puumala hantavirus strains from Austria. *Scand. J. Inf. Dis* 38 (6): 512-519, 2006.
17. Skarpaas, T., Golovljova, I., Vene, S., Ljøstad, U., Sjursen, H., Plyusnin, A., and Lundkvist, Å. First molecular identification of tick-borne encephalitis virus from Norway and Denmark. *Emerging Infectious Diseases* 12(7):1136-1138, 2006.
18. Cvetko, L., Turk, N., Markotic, A., Milas, Z., Margaletic, J., Miletic-Medved, M., Plyusnin, A., Baranton, G, Postic, D., Avzic-Zupanc, T. Dual infection with *Puumala virus* and *Leptospira interrogans* serovar Lora in a bank vole (*Clethrionomys glareolus*). *Am J Trop Med Hyg.* 74(4):612-614, 2006.
19. Hugot, J-P, Plyusnina, A., Herbreteau, V., Nemirov, K., Laakkonen, J., Lundkvist, Å., Supputamongkol, Y., Henttonen, H. and Plyusnin, A. Genetic analysis of Thailand hantavirus in *Bandicota indica* trapped in Thailand. *Virology J* 3(1):72 (Sep5), 2006
20. Nevas, M., Lindstrom, M., Horman, A., Keto-Timonen, R. and Korkeala, H. Contamination routes of *Clostridium botulinum* in the honey production environment. *Environ Microbiol.* 2006; 8:1085-94.

Abstracts:

1. Hörman, A., Nevas, M., Lindström, M., Hänninen, M-L and Korkeala, H. Detection of Botulinum neurotoxin (BoNT) type B in water sample. NBC 2006 Symposium on chemical, biological, nuclear and radiological threats – A safety & security challenge, Tampere, Finland, 18.-21.06.2006. Abstract.
2. Matero, P., Piiparinen, H., Rantakokko-Jalava, K., Nikkari, S. Identification of the potential biowarfare agent *Brucella* spp. using a hand-held real-time PCR instrument, RAZOR. NBC 2006 Symposium on chemical, biological, nuclear and radiological threats - A safety & security challenge, Tampere, Finland, 18.-21.06.2006. Abstract and poster.
3. Rissanen, S., Jousela, I., Jeong, J-R., Rintamäki, H. Performing medical procedures in NBC procedures in NBC protective ensembles in warm and cold environments. NBC 2006 Symposium on chemical, biological, nuclear and radiological threats – A safety & security challenge, Tampere, Finland, 18.-21.06.2006. Abstract and poster.
4. Santonen, T., Komulainen, H., Peltonen, K., Rizzo, A., Nieminen, K., Jousela, I., Liponen, M., Hoppu, K., Talka, T., Björk, H., Haikala, O., Söder, J., Riihimäki, V. Finnish centre of expertise on chemical threats – a network of expert institutions supporting responsible authorities to improve their preparedness to chemical threats.

NBC 2006 Symposium on chemical, biological, nuclear and radiological threats – A safety & security challenge, Tampere, Finland, 18.-21.06.2006. Abstract.

5. Skottman, T., Piiparinen, H., Hyytiäinen, H., Mylly, V., Skurnik, M., Nikkari, S. Simultaneous real-time PCR detection of *Bacillus anthracis*, *Francisella tularensis* and *Yersinia pestis*. ICAAC 26-30.9.2006; San Francisco, CA, USA. Poster.

In Finnish:

1. Laiho A, Virtala A-M, Ek-Kommonen C, Vapalahti O. Lintuinfluenssa - kirjallisuuskatsaus ja villilintujen alustava kartoitustutkimus Suomessa 2003. Suomen eläinlääkärilehti 2006
2. Kurkela S, Pakarinen L, Vapalahti O. Chikungunya-virusepidemia leviää Intian valtamerellä. Suomen Lääkärilehti 2006;23:2502-3
3. Jousela, I. C-suojelulääkintä. Castrén, M., Ekman, S., Martikainen, M., Sahi, T., Söder, J. (toim.). Suuronnettomuusopas. Duodecim 2006; 342-64. ISBN 951-656-202-7.
4. Laapio, H, Jousela, I. Puolustusvoimat, Toiminta suuronnettomuustilanteessa. Castrén, M., Ekman, S., Martikainen, M., Sahi, T., Söder, J. (toim.). Suuronnettomuusopas. Duodecim 2006; 164-71. ISBN 951-656-202-7.
5. Nikkari, S. B-suojelulääkintä. Castrén, M., Ekman, S., Martikainen, M., Sahi, T., Söder, J. (toim.). Suuronnettomuusopas. Duodecim 2006; 333-41. ISBN 951-656-202-7.
6. Jousela, I. Tilannekatsaus C-rintamalta – ajankohtaista C-suojelulääketieteestä. Huhtinen, A-M., Toiskallio, J. (toim.). Maanpuolustuskorkeakoulu – kehittyvä sotatieteellinen yliopisto. Maanpuolustuskorkeakoulu 2006; 188-200. ISBN 951-25-1690-X.
7. Nikkari, S. Biologiset uhat ja suojelulääketieteen mahdollisuudet niiden torjumiseksi. Huhtinen, A-M., Toiskallio, J. (toim.). Maanpuolustuskorkeakoulu – kehittyvä sotatieteellinen yliopisto. Maanpuolustuskorkeakoulu 2006; 240-252. ISBN 951-25-1690-X.

Active promotion of contacts

No international conferences, symposia, seminars, and other similar forums are planned for the year 2007

1. Planned international conferences, symposia, seminars, and other similar forums for exchange

For each such event, the following information should be provided:

- name of the conference:
- arranging organizations:
- time:
- place:
- main subject(s) for the conference:
- conditions for participation:
- point of contact for further, information, registration:

Declaration of legislation, regulations and other measures

<u>Relating to</u>	<u>Legislation</u>	<u>Regulations</u>	<u>Other measures</u>	<u>Amended since last year</u>
(a) Development, production stockpiling, acquisition or retention of microbial or other biological agents, or toxins, weapons, equipment and means of delivery specified in Article I	YES	YES	YES	NO
(b) Exports of micro-organisms* and toxins	YES	YES	YES	NO
(c) Imports of micro-organisms* and toxins	YES	YES	YES	NO

* Micro-organisms pathogenic to man, animals and plants in accordance with the Convention.

Declaration of past activities in offensive and/or defensive biological research and development programmes

Nothing to declare.

CONFIDENCE BUILDING MEASURE G

Declaration of vaccine production facilities

There are no vaccine production facilities in Finland.

Declaration of legislation, regulations and other measures

Additional information

Finland's legislation on biological weapons is based on the Biological Weapons Act 257/1975 and Decree 258/1975. Corresponding penal provisions were included in the Penal Code, chapter 11, section 7 b (Breach of the prohibition of biological weapons), with amendment 17/2003. Penal Code (39/1889) chapter 11, section 1 (War Crime), chapter 5, section 3 (Complicity in an offence) and section 6 (Abetting), chapter 34, sections 4 (Health endangerment) and 5 (Aggravated health endangerment), and chapter 34 a (Terrorist offences) are also applicable.

Exports of micro-organisms and toxins are regulated by the Act on the Control of Export of Dual-Use Goods (562/1996, as amended by Acts 891/2000, 884/2001 and 581/2003), Government Decree on the Control of Export of Dual-Use Goods (924/2000 as amended by Decree 924/2000) and EC Council Regulation 1334/2000. Corresponding penal provisions were incorporated in the Penal Code (39/1889), chapter 46, sections 1-3 by Acts 769/1990, 1522/1994 and 706/1997. Since 2003, the authority responsible for export controls of micro-organisms and toxins is the Ministry for Foreign Affairs (Export Control Unit).

Imports of micro-organisms and toxins are regulated by the Biological Weapons Act 257/1975 and Decree 258/1975. Transports of micro-organisms and toxins are also regulated by the EC Council Directives 94/55/EEC and 96/49/EEC, the Communicable Diseases Act 583/1986 (as amended), section 33; Communicable Diseases Decree 786/1986 (as amended); Act on the Transport of Dangerous Goods (719/1994 as amended) and related decrees, Act on Protecting Plant Health (702/2003), section 7, and related decrees, Act on Animal Diseases (55/1980 as amended) and related decrees, Act on Veterinary Border Control (1192/1996 as amended) and related decrees. The corresponding penal provisions are included in the Penal Code (39/1889 as amended), chapter 44, section 2 (Health protection violation), chapter 44, section 13 (Transport of dangerous substances offence) and chapter 46, section 4 (Smuggling).